Nanotechnology Breath Test Could Help ID Gastric CA Earlier

This article originally appeared here.
Share this content:
Nanotechnology Breath Test Could Help ID Gastric CA Earlier
Nanotechnology Breath Test Could Help ID Gastric CA Earlier

(HealthDay News) -- A novel technology senses small changes in the levels of particular compounds in exhaled breath, and accurately identifies changes that signal the development of gastric cancer, according to a study published online April 13 in Gut.

The new test uses nanotechnology that analyzes a set of atoms called nanoarrays. In this case, the array includes atoms from breath samples and the computer looks for the amount of specific compounds that are linked to gastric cancer. Nanoarray analysis is accurate, simple, and inexpensive, the researchers said.

Christine Metz, Ph.D., director of the laboratory of medicinal biochemistry at the Feinstein Institute for Medical Research in Manhasset, N.Y., and colleagues collected two breath samples from 484 people, 99 of whom had been diagnosed with gastric cancer but had not yet had chemotherapy or radiation treatments. The patients were asked about their smoking and drinking habits and tested for infection with Helicobacter pylori. The first breath sample was analyzed using a technique that measures the various organic compounds in exhaled breath. The second sample was analyzed using a nanoarray.

The patterns identified using nanoarray technology accurately distinguished the different precancerous stages, identifying patients at low and high risk for developing gastric cancer, the researchers said. The findings did not change when the researchers took into account age, alcohol use, and the use of proton pump inhibitors.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »